CELC Celcuity Inc.

MIXED Impact: 6/10 424B5
Horizon weeks Filed Jun 5, 2026 Processed 1d 12h ago SEC 0001493152-26-027395
Notable filing: 424B5

Price Chart

Loading chart...

Executive Summary

Celcuity is issuing $500M of 0.250% convertible senior notes due 2032 (plus $75M over-allotment). Net proceeds of ~$484.3M will fully repay the $137.9M secured term loan facility and fund working capital, commercial launch, and pipeline expansion through 2028. The de-levering to zero secured debt is a significant credit-positive event, but the large debt raise (~$201M prior converts + $500M new, totaling ~$701M) adds substantial leverage and potential dilution if converted.

Actionable Insight

Convertible note offering removes restrictive secured debt and extends runway into 2028, supporting commercial launch. However, the massive debt load (~$701M) and potential dilution from conversion at ~$124.53/share cap upside. Monitor FDA PDUFA on July 17 — approval could de-risk the conversion premium. Preferred shares would benefit from the de-levering to unsecured debt.

Key Facts

  • $500M aggregate principal of 0.250% convertible senior notes due 2032
  • $75M over-allotment option, total $575M if fully exercised
  • Initial conversion price ~$124.53/share, ~40% premium to $88.95 stock price on June 3
  • Net proceeds ~$484.3M (or ~$557M with over-allotment)
  • Proceeds to fully repay $137.9M secured term loan, eliminating all secured debt
  • Post-offering, total long-term debt rises from $339.1M to $701.3M
  • Maturity August 1, 2032; interest 0.250% paid semi-annually
  • Not redeemable before August 6, 2029; convertible upon stock price conditions or certain corporate events
  • Mandatory contingent conversion triggers if stock exceeds 130% of conversion price for 20 of 30 trading days
  • FDA PDUFA date for gedatolisib NDA in PIK3CA WT breast cancer is July 17, 2026
  • Positive Phase 3 VIKTORIA-1 MT data announced June 2, 2026 — sNDA planned Q3 2026

Financial Impact

De-levering: $137.9M secured debt eliminated; new debt: $500M-$575M. Net cash infusion ~$484M after expenses. Total debt rises from $339M to $701M. Prepayment fee of ~$2.6M incurred.

debtdilutionliquidityinterest expense

Risk Factors

  • ~$701M total debt after offering significantly increases financial leverage
  • Potential dilution from conversion: ~4M shares per $500M at $124.53, plus ~4M from existing 2031 converts at $51.30
  • Unsecured notes rank equal with existing 2031 converts but effectively junior to any future secured debt
  • No public trading market expected for the notes; illiquidity premium
  • If stock does not appreciate above $124.53, convert notes remain out of the money — overhang without upside
  • PIK element on prior term loan was expensive (~7.75%+2.85%); replacement with 0.25% coupon is cheaper but riskier (convertible)

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
94% bullish (18 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001493152-26-027395
Exhibit: ex107.htm0001493152-26-027395
Document: 0001493152-26-027395-index-headers.html0001493152-26-027395
Document: 0001493152-26-027395-index.html0001493152-26-027395
Document: 0001493152-26-027395.txt0001493152-26-027395
10 reports for CELC
Performance horizon
20% Hit rate 1 of 5 directional calls best @ T+5▲ +0.40%May 14, 2026
Filters
Rows
Reports for CELC — sortable, filterable
Type Now
Jun 5, 2026
1d ago
424B5
MIXED ★ 6/10
awaiting T+1
Jun 4, 2026
2d ago
Press Release
MIXED ★ 6/10
awaiting T+1
Jun 3, 2026
3d ago
Press Release
BEARISH ★ 6/10
$88.95 $92.47▼ −3.96%▼ −3.56%$88.28 (+0.75%)
Jun 3, 2026
3d ago
424B5
BEARISH ★ 6/10
$88.95 $92.47▼ −3.96%▼ −3.56%$88.28 (+0.75%)
Jun 2, 2026
4d ago
8-K
BULLISH ★ 8/10
$91.42 $88.95▼ −2.70%▼ −2.01%$88.28 (−3.43%)
May 14, 2026
23d ago
Press Release
BULLISH ★ 7/10
$137.68 $132.18▼ −3.99%▼ −3.93%$88.28 (−35.88%)
May 7, 2026
4w ago
Press Release
NEUTRAL ★ 3/10
$130.71 $131.06▲ +0.27%▼ −0.56%$88.28 (−32.46%)
May 4, 2026
4w ago
144
NEUTRAL ★ 2/10
$144.98 $141.69▼ −2.27%▼ −3.06%$88.28 (−39.11%)
May 1, 2026
5w ago
Press Release
BULLISH ★ 8/10
$144.98 $141.69▼ −2.27%▼ −3.06%$88.28 (−39.11%)
Mar 25, 2026
10w ago
Press Release
MIXED ★ 8/10
$114.81 $106.02▼ −7.66%▼ −5.98%$88.28 (−23.11%)
Showing 10 of 10

US Market Status

Market Closed — Opens Mon (14h 56m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access